Financial Performance - InnoCare Pharma's sales revenue for the third quarter of 2022 reached RMB 195.65 million, a decrease of 77.76% compared to the same period last year[6] - The company's total revenue for the first nine months of 2022 was RMB 441.61 million, a 115% increase after excluding the impact of a strategic partnership with BeiGene in Q3 2021[5] - The company's operating revenue for the current reporting period decreased by 77.76% compared to the same period last year, primarily due to a high one-time technology licensing income recognized in the previous year[11] - Total operating revenue for the first three quarters of 2022 was CNY 441,612,184.36, a decrease from CNY 981,429,657.21 in the same period of 2021[23] - Net profit for the third quarter of 2022 was a loss of CNY 842,652,515.00, contrasting with a profit of CNY 87,305,248.88 in the same quarter of 2021[24] - The net loss attributable to shareholders for Q3 2022 was RMB 392.81 million, a 232.11% increase compared to the same period last year[7] - The net profit attributable to shareholders for the current reporting period decreased by 232.11% compared to the same period last year, influenced by the high technology licensing income from the previous year[11] Research and Development - Sales of the drug Orelabrutinib (宜诺凯®) amounted to RMB 183 million in Q3 2022, representing a 64% increase from Q2 2022 and a 129% increase year-on-year for the first nine months of 2022[4] - Research and development expenses for the first nine months of 2022 totaled RMB 475 million, reflecting a 30% increase compared to the previous year[5] - The company's R&D expenditure accounted for 100.71% of its revenue in Q3 2022, an increase of 55.14 percentage points year-on-year[7] - The company's R&D investment as a percentage of operating revenue increased by 55.14 percentage points for the current reporting period, reflecting a significant increase in R&D spending[12] - The company has 13 products in various stages of clinical trials, indicating a robust pipeline for future growth[4] Assets and Liabilities - The total assets of InnoCare Pharma as of Q3 2022 were RMB 10.43 billion, a 40.68% increase compared to the previous year[7] - The total assets increased by 40.68% compared to the end of the previous period, mainly due to the increase in funds raised from the A-share listing[12] - The total liabilities as of the end of the third quarter of 2022 were CNY 2,649,251,273.58, compared to CNY 1,756,050,524.82 at the end of the previous year[22] - The total equity attributable to shareholders of the parent company was CNY 7,736,172,992.15, an increase from CNY 5,604,559,524.19 in the previous year[22] Cash Flow and Liquidity - As of September 30, 2022, the company held cash and cash equivalents exceeding RMB 9.2 billion, ensuring sufficient liquidity for ongoing projects[5] - Operating cash flow for the first nine months was negative at -395,317,143.03, compared to a positive cash flow of 279,981,380.12 in the same period last year[27] - Total cash inflow from operating activities was 542,296,157.15, while cash outflow was 937,613,300.18, resulting in a net cash flow from operating activities of -395,317,143.03[27] - Cash inflow from investment activities totaled 144,458,064.46, with cash outflow amounting to 1,862,513,669.37, leading to a net cash flow from investment activities of -1,718,055,604.91[28] - Financing activities generated a cash inflow of 3,129,667,311.83, while cash outflow was 23,645,843.57, resulting in a net cash flow from financing activities of 3,106,021,468.26[28] - The company reported a net increase in cash and cash equivalents of 1,176,888,160.90, bringing the ending balance to 4,414,372,466.48[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 118,973[14] - The top ten shareholders held a significant portion of shares, with HKSCC NOMINEES LIMITED owning 724,573,837 shares, representing 41.07%[16] - The company reported a total of 1,589,900 shares lent out through margin trading as of the reporting period[17] - The company has engaged in strategic placements, with Guangzhou High-tech Zone Technology Holdings Group acquiring 8,975,521 shares[17] Other Financial Metrics - The weighted average return on equity was -7.53% for Q3 2022, a decrease of 12.81 percentage points from the previous year[7] - The company reported a foreign exchange loss of CNY -13,278,019.54 in the third quarter of 2022, compared to a loss of CNY -38,875,062.81 in the previous year[24] - The total comprehensive income for the third quarter of 2022 was CNY -279,487,002.07, compared to CNY 84,340,648.28 in the same quarter of 2021[25] - Basic earnings per share for the third quarter of 2022 were CNY -0.59, compared to CNY 0.06 in the same quarter of 2021[25] - The company reported a decrease in basic earnings per share of ¥233.33 for the current reporting period, influenced by the high technology licensing income from the previous year and foreign exchange losses[11]
诺诚健华(09969) - 2022 Q3 - 季度财报